Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) Projects Robust H1 Profit Growth: Net Attributable Income Forecast at RMB 170M-185M, Surging 13.92%-23.97%

Market Watcher07-15

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) has unveiled its preliminary financial projections for the first half of 2025, signaling a robust earnings trajectory. The biopharmaceutical leader anticipates net profit attributable to shareholders reaching between RMB 170 million and RMB 185 million – a solid year-on-year expansion of 13.92% to 23.97%.

Stripping out non-recurring items, the company's core operational performance appears even stronger. Adjusted net profit is expected to land in the range of RMB 166 million to RMB 181 million, accelerating at a faster clip of 16.96% to 27.56% compared with the same period last year. This dual growth momentum underscores the company's operational efficiency and sustained market competitiveness.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153684097?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-15 22:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153684097","market":"hk","top_or_hot":-1,"title":"Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) Projects Robust H1 Profit Growth: Net Attributable Income Forecast at RMB 170M-185M, Surging 13.92%-23.97%","media":"Market Watcher","content":"<p>Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) has unveiled its preliminary financial projections for the first half of 2025, signaling a robust earnings trajectory. The biopharmaceutical leader anticipates net profit attributable to shareholders reaching between RMB 170 million and RMB 185 million – a solid year-on-year expansion of 13.92% to 23.97%.</p>\n<p>Stripping out non-recurring items, the company's core operational performance appears even stronger. Adjusted net profit is expected to land in the range of RMB 166 million to RMB 181 million, accelerating at a faster clip of 16.96% to 27.56% compared with the same period last year. This dual growth momentum underscores the company's operational efficiency and sustained market competitiveness.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) Projects Robust H1 Profit Growth: Net Attributable Income Forecast at RMB 170M-185M, Surging 13.92%-23.97%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Wolwo Bio-Pharmaceutical (300357.SZ) Projects Robust H1 Profit Growth: Net Attributable Income Forecast at RMB 170M-185M, Surging 13.92%-23.97%\n</h2>\n\n<h4 class=\"meta\">\n\n2025-07-15 22:06 北京时间&nbsp;&nbsp;&nbsp;<strong>Market Watcher</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) has unveiled its preliminary financial projections for the first half of 2025, signaling a robust earnings trajectory. The biopharmaceutical ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1153684097","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153684097","pubTimestamp":1752588371,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) has unveiled its preliminary financial projections for the first half of 2025, signaling a robust earnings trajectory. The biopharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"laohu8.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"300357":"我武生物","BK0239":"医药制造","BK0028":"国家队"},"translate_title":"浙江沃尔沃生物制药（300357.SZ）预计上半年利润强劲增长：预计归属净利润为1.7亿-1.85亿元，同比增长13.92%-23.97%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300357":1},"content_text":"Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) has unveiled its preliminary financial projections for the first half of 2025, signaling a robust earnings trajectory. The biopharmaceutical leader anticipates net profit attributable to shareholders reaching between RMB 170 million and RMB 185 million – a solid year-on-year expansion of 13.92% to 23.97%.\nStripping out non-recurring items, the company's core operational performance appears even stronger. Adjusted net profit is expected to land in the range of RMB 166 million to RMB 181 million, accelerating at a faster clip of 16.96% to 27.56% compared with the same period last year. This dual growth momentum underscores the company's operational efficiency and sustained market competitiveness.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153684097","isCrawlerRequest":true}